News
Merck KGaA announces mutual decision to end bintrafusp alfa agreement with GSK.
Merck KGaA, a leading science and technology company, announced a mutual decision with GSK to terminate their agreement on bintrafusp alfa, effective September 30, 2021.
The decision is based on the clinical trial data generated to date, most notably the previously reported results from the INTR@PID Lung 037 study, which did not replicate the encouraging data observed in earlier studies. Based on the data generated during the agreement, no milestone payments were made by GSK and no future milestone obligations remain.
Condition: Biliary Tract Cancer
Type: drug
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.